Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
AYGESTIN vs NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium. Ethinyl estradiol is an estrogen that provides cycle control and contributes to contraceptive efficacy. Ferrous fumarate provides iron supplementation.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol, and 75 mg ferrous fumarate) orally once daily for 28 days, without interruption. Take the first tablet on the first day of menstrual bleeding.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Norethindrone: 8-11 hours (terminal). Ethinyl estradiol: 10-20 hours (terminal). Clinical context: Steady-state achieved after 5-7 days; half-life supports once-daily dosing.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Norethindrone acetate and ethinyl estradiol are primarily excreted in urine (40-60% as metabolites) and feces (20-40% as metabolites). Ferrous fumarate is absorbed and iron is utilized; unabsorbed iron is excreted in feces.
Category C
Category D/X
Progestin
Progestin